Abstract 458P
Background
Venous Thromboembolism (VTE) is a common cardiovascular disease affecting cancer patient with related poor prognosis and short survival. Different scoring systems and certain genetic polymorphisms were used to predict patient's risk for VTE. This study aimed to investigate the association between TSPAN15 (rs78707713) and SLC44A2 (rs2288904) genetic polymorphisms and VTE in cancer patients in correlation with PROTECHT scoring system and survival.
Methods
This case control study was carried out on 100 cancer patients, group I included 50 consecutive cancer patients with VTE, and group II included 50 selected cancer patients without VTE with age and cancer diagnosis matched to group I as a control. Full history taking and clinical examination and all clinical data were recorded. Laboratory investigations including CBC, coagulation profile and analysis of TSPAN15 (rs78707713) and SLC44A2 (rs2288904) SNPs by PCR were assessed. Radiological imaging of VTE by duplex ultrasound, CT pulmonary angiography were done according to the clinical scenario. PROTECHT score and survival analysis were calculated.
Results
Cancer patients with VTE had high tumor grade, increased incidence of metastasis with shorter progression free survival (PFS) compared with cancer patients without VTE. Partial immobilization and hospitalization were significantly associated with the occurrence of VTE in cancer patients. Regarding cancer treatment, the use of gemcitabine-based chemotherapy was associated with an increased risk for VTE. The most frequent SLC44A2 (rs2288904) genotype was GG followed by AG in cancer patients with VTE. Whereas GG and AG genotypes were equally distributed in cancer patients without VTE, The GG genotype had high risk PROTECHT score compared with AA and AG genotypes. The commonest TSPAN15 (rs78707713) genotypes were TC and CC in cancer patients with VTE versus TC and TT in cancer patients without VTE. The CC genotype had high PROTECHT score points compared with TC and TT genotypes. Furthermore, TC and CC cancer patients with VTE had significantly high tumor grade.
Conclusions
Screening of SLC44A2 (rs2288904) and TSPAN15 (rs78707713) genetic variants may enhance the ability to predict VTE risk in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufeya University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract